Status:
RECRUITING
Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV
Lead Sponsor:
University of Hawaii
Conditions:
Obesity and Overweight
HIV
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a prospective cohort study of 12 overweight (with one or more weight-related condition) or obese adults with well controlled HIV-1 on antiretroviral therapy (ART). An initial dose of tirzepati...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- HIV-1 infection (well controlled)
- Documented HIV-1 infection ≥ 1 year prior to study entry (ELISA confirmed by Western blot or HIV-1 RNA) AND
- HIV-1 RNA \<200 copies/mL for ≥ 6 months
- Stable ART
- · Receiving a stable antiretroviral regimen for at least 1 year prior to study entry
- Overweight
- BMI ≥27 kg/m2 plus at least one weight-related condition (defined as a medical history of dyslipidemia, hypertension, cardiovascular disease, or obstructive sleep apnea) OR Obese
- BMI ≥ 30 kg/m2
Exclusion
Key Trial Info
Start Date :
November 12 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2026
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT06935838
Start Date
November 12 2025
End Date
July 31 2026
Last Update
November 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
John A Burns School of Medicine
Honolulu, Hawaii, United States, 96813